Schrodinger, Inc. (SDGR)
| Market Cap | 5.45B |
| Revenue (ttm) | 108.10M |
| Net Income (ttm) | -24.46M |
| Shares Out | 56.32M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $77.90 |
| Previous Close | $78.36 |
| Change ($) | -0.46 |
| Change (%) | -0.59% |
| Day's Open | 78.30 |
| Day's Range | 76.35 - 78.56 |
| Day's Volume | 579,040 |
| 52-Week Range | 40.12 - 117.00 |
NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger presented new preclinical data from its CDC7 inhibitor program during AACR 21 Annual Virtual Meeting.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that the company will participate in the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery.
NEW YORK--(BUSINESS WIRE)--Schrödinger will host a webcast to review the preclinical data being presented at the AACR Annual Meeting.
These three companies have just one thing in common: the potential to offer a long-term windfall for stockholders.
Wood's biotech fund owns almost $200 million worth of Schrodinger, about 2% of the company. Here's why she's an investor.
NEW YORK--(BUSINESS WIRE)--Schrödinger will participate in the virtual Credit Suisse 2021 Healthcare Innovators Series on March 23, 2021.
This drug discovery company's stock just took a major hit.
NEW YORK--(BUSINESS WIRE)---- $SDGR #AACR21--Schrödinger announced that preclinical data from its CDC7 program will be presented at the AACR Annual Meeting.
NEW YORK--(BUSINESS WIRE)---- $SDGR #earnings--Schrödinger today reported financial results for the fourth quarter and full year 2020.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that management will provide a corporate overview during the H.C. Wainwright Global Life Sciences Conference.
NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it has expanded its collaboration with Google Cloud.
Schrodinger is an exciting, next generation drug development and software player. However, at its core, it is a molecular modelling company, leading to vast opportunities. The TAM of the markets in whic...
The biotechnology exchange-traded fund SPDR S&P Biotech ETF (NYSE: XBI) is up around 50% in 2020 and Jefferies' managing director Michael Yee says the valuations are not only justified but sustainable i...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its ...
The company announced a partnership with Bristol Myers Squibb.
Schrödinger Inc. shares jumped about 8% in premarket trade Monday, after the company announced a drug discovery agreement with Bristol Myers Squibb Co. that could net it up to $2.7 billion in milestone ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collabor...
Schrödinger stock is almost at half the price since peaking in the summer. Stock dilution hurt investors, but the market is betting on its software growth.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q3 2020 Results - Earnings Call Transcript
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results fo...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that members of the ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will present data...
NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced it will host a conference ...
Big Tech companies have been the hottest stocks on Wall Street all year, pre- and post-pandemic. But some experts think it's time for a new crop of dynamic up-and-comers in fields like virtual reality a...
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Schrödinger, Inc. has exhibited a stock price slide since July, even as revenue growth continues above expectations.
Three great performing yet relatively unknown med-tech stocks with a high upside.
Schrödinger's computational platform integrates physics-based methods with machine-learning techniques to enable drug discovery and development of novel materials.
Schrödinger has an innovative computational platform that accelerates the discovery of new molecules for use in therapeutics and industrial materials.
Schrodinger (SDGR) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q2 2020 Results - Earnings Call Transcript
SHANGHAI and NEWYORK, July 28, 2020 /PRNewswire/ -- Viva Biotech Holdings (1873.HK) and Schrödinger, Inc. (Nasdaq: SDGR) today announced a strategic collaboration to expand the reach of structure-based ...
A company that can speed up drug discovery; one that is already partnering with the world’s 20 biggest drug companies and appears to be just scratching the surface of its potential.
Schrödinger, Inc. (SDGR) CEO Ramy Farid on Q1 2020 Results - Earnings Call Transcript
Schrodinger - Taking Drug Discovery To The 'Space Age'
The company continues to coast on a positive note from Citron Research.
1 hot IPO plus 1 comparison to Tesla equals 1/3 more stock value.
Notable activist short seller Andrew Left and his Citron Research firm said in a new report Schrodinger Inc (NASDAQ: SDGR) is the "most important IPO" in the past five years.
This IPO has been a success regardless.
About SDGR
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharma... [Read more...]
| Industry Health Information Services | IPO Date Feb 6, 2020 |
| Stock Exchange NASDAQ | Ticker Symbol SDGR |
Financial Performance
In 2020, Schrodinger's revenue was $108.10 million, an increase of 26.36% compared to the previous year's $85.54 million. Losses were -$24.46 million, -0.44% less than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for Schrodinger stock is "Buy." The 12-month stock price forecast is 92.75, which is an increase of 19.06% from the latest price.